Press Releases

Press Releases

Samsung Biologics announces its financial results for 1Q 2017

 

Samsung Biologics records sales of KRW 107.6 billion and profits of KRW 3.4 billion in 1Q 2017

 

 

-    Sales improved KRW 2.1 billion and Profits improved KRW 4.1 billion compared to last quarter 

 

 

 

Samsung BioLogics Co., Ltd. (CEO: Tae Han Kim) today announced its financial results for the first quarter in 2017. The company posted quarterly sales of KRW 107.6 billion and quarterly operating profits of KRW 3.4 billion.

 

Sales of Samsung Biologics increased KRW 2.1 billion (1.9%) as its product shipments increased. Also as sales increased and SG&A (Selling, General and Administrative Expenses) decreased, operating profits increased KRW 4.1 billion to turn profitable.

 

It also posted net loss of KRW 33.1 billion, reflecting the equity method of biosimilar development and clinical expenses for the company’s subsidiary, including Samsung Bioepis and Archigen Biotech.  

 


※ Samsung Biologics Financial Result 1Q 2017                                           (Billion Won)

 

  1Q 2017

4Q 2016

QoQ

 Sales

107.6

 105.5

+2.1(1.9%) 

 Operating Profit

3.4

-0.7

 +4.1(Profitable)

 Net Profit

-33.1

-57

 +23.9(41.9%)

 

 

 

Samsung Biologics records sales of KRW 107.6 billion and profits of KRW 3.4 billion in 1Q 2017

 

 

-    Sales improved KRW 2.1 billion and Profits improved KRW 4.1 billion compared to last quarter 

 

 

 

Samsung Biologics Co., Ltd. (CEO: Tae Han Kim) today announced its financial results for the first quarter in 2017. The company posted quarterly sales of KRW 107.6 billion and quarterly operating profits of KRW 3.4 billion.

 

Sales of Samsung Biologics increased KRW 2.1 billion (1.9%) as its product shipments increased. Also as sales increased and SG&A (Selling, General and Administrative Expenses) decreased, operating profits increased KRW 4.1 billion to turn profitable.

 

It also posted net loss of KRW 33.1 billion, reflecting the equity method of biosimilar development and clinical expenses for the company’s subsidiary, including Samsung Bioepis and Archigen Biotech.  

 


※ Samsung Biologics Financial Result 1Q 2017                                           (Billion Won)

 

  1Q 2017

4Q 2016

QoQ

 Sales

107.6

 105.5

+2.1(1.9%) 

 Operating Profit

3.4

-0.7

 +4.1(Profitable)

 Net Profit

-33.1

-57

 +23.9(41.9%)

 

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION